These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 19213845)

  • 1. Ablation of the Galnt3 gene leads to low-circulating intact fibroblast growth factor 23 (Fgf23) concentrations and hyperphosphatemia despite increased Fgf23 expression.
    Ichikawa S; Sorenson AH; Austin AM; Mackenzie DS; Fritz TA; Moh A; Hui SL; Econs MJ
    Endocrinology; 2009 Jun; 150(6):2543-50. PubMed ID: 19213845
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phenotypic and Genotypic Characterization and Treatment of a Cohort With Familial Tumoral Calcinosis/Hyperostosis-Hyperphosphatemia Syndrome.
    Ramnitz MS; Gourh P; Goldbach-Mansky R; Wodajo F; Ichikawa S; Econs MJ; White KE; Molinolo A; Chen MY; Heller T; Del Rivero J; Seo-Mayer P; Arabshahi B; Jackson MB; Hatab S; McCarthy E; Guthrie LC; Brillante BA; Gafni RI; Collins MT
    J Bone Miner Res; 2016 Oct; 31(10):1845-1854. PubMed ID: 27164190
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dietary phosphate restriction normalizes biochemical and skeletal abnormalities in a murine model of tumoral calcinosis.
    Ichikawa S; Austin AM; Gray AK; Allen MR; Econs MJ
    Endocrinology; 2011 Dec; 152(12):4504-13. PubMed ID: 22009723
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel GALNT3 mutations causing hyperostosis-hyperphosphatemia syndrome result in low intact fibroblast growth factor 23 concentrations.
    Ichikawa S; Guigonis V; Imel EA; Courouble M; Heissat S; Henley JD; Sorenson AH; Petit B; Lienhardt A; Econs MJ
    J Clin Endocrinol Metab; 2007 May; 92(5):1943-7. PubMed ID: 17311862
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A mouse with an N-Ethyl-N-nitrosourea (ENU) Induced Trp589Arg Galnt3 mutation represents a model for hyperphosphataemic familial tumoural calcinosis.
    Esapa CT; Head RA; Jeyabalan J; Evans H; Hough TA; Cheeseman MT; McNally EG; Carr AJ; Thomas GP; Brown MA; Croucher PI; Brown SD; Cox RD; Thakker RV
    PLoS One; 2012; 7(8):e43205. PubMed ID: 22912827
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hyperphosphatemic familial tumoral calcinosis: genetic models of deficient FGF23 action.
    Folsom LJ; Imel EA
    Curr Osteoporos Rep; 2015 Apr; 13(2):78-87. PubMed ID: 25656441
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumoral calcinosis presenting with eyelid calcifications due to novel missense mutations in the glycosyl transferase domain of the GALNT3 gene.
    Ichikawa S; Imel EA; Sorenson AH; Severe R; Knudson P; Harris GJ; Shaker JL; Econs MJ
    J Clin Endocrinol Metab; 2006 Nov; 91(11):4472-5. PubMed ID: 16940445
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic rescue of glycosylation-deficient Fgf23 in the Galnt3 knockout mouse.
    Ichikawa S; Gray AK; Padgett LR; Allen MR; Clinkenbeard EL; Sarpa NM; White KE; Econs MJ
    Endocrinology; 2014 Oct; 155(10):3891-8. PubMed ID: 25051439
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A case of familial tumoral calcinosis/hyperostosis-hyperphosphatemia syndrome due to a compound heterozygous mutation in GALNT3 demonstrating new phenotypic features.
    Dumitrescu CE; Kelly MH; Khosravi A; Hart TC; Brahim J; White KE; Farrow EG; Nathan MH; Murphey MD; Collins MT
    Osteoporos Int; 2009 Jul; 20(7):1273-8. PubMed ID: 18982401
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of mutant UDP-N-acetyl-alpha-D-galactosamine-polypeptide N-acetylgalactosaminyltransferase 3 in regulating serum intact fibroblast growth factor 23 and matrix extracellular phosphoglycoprotein in heritable tumoral calcinosis.
    Garringer HJ; Fisher C; Larsson TE; Davis SI; Koller DL; Cullen MJ; Draman MS; Conlon N; Jain A; Fedarko NS; Dasgupta B; White KE
    J Clin Endocrinol Metab; 2006 Oct; 91(10):4037-42. PubMed ID: 16868048
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Loss of the disease-associated glycosyltransferase Galnt3 alters Muc10 glycosylation and the composition of the oral microbiome.
    Peluso G; Tian E; Abusleme L; Munemasa T; Mukaibo T; Ten Hagen KG
    J Biol Chem; 2020 Jan; 295(5):1411-1425. PubMed ID: 31882545
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical variability of familial tumoral calcinosis caused by novel GALNT3 mutations.
    Ichikawa S; Baujat G; Seyahi A; Garoufali AG; Imel EA; Padgett LR; Austin AM; Sorenson AH; Pejin Z; Topouchian V; Quartier P; Cormier-Daire V; Dechaux M; Malandrinou FCh; Singhellakis PN; Le Merrer M; Econs MJ
    Am J Med Genet A; 2010 Apr; 152A(4):896-903. PubMed ID: 20358599
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Miscellaneous non-inflammatory musculoskeletal conditions. Hyperphosphatemic familial tumoral calcinosis (FGF23, GALNT3 and αKlotho).
    Farrow EG; Imel EA; White KE
    Best Pract Res Clin Rheumatol; 2011 Oct; 25(5):735-47. PubMed ID: 22142751
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Runx2 Regulates
    Jiang Q; Qin X; Moriishi T; Fukuyama R; Katsumata S; Matsuzaki H; Komori H; Matsuo Y; Sakane C; Ito K; Hojo H; Ohba S; Komori T
    Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38396954
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Familial tumoral calcinosis and the role of O-glycosylation in the maintenance of phosphate homeostasis.
    Chefetz I; Sprecher E
    Biochim Biophys Acta; 2009 Sep; 1792(9):847-52. PubMed ID: 19013236
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A homozygous missense mutation in human KLOTHO causes severe tumoral calcinosis.
    Ichikawa S; Imel EA; Kreiter ML; Yu X; Mackenzie DS; Sorenson AH; Goetz R; Mohammadi M; White KE; Econs MJ
    J Clin Invest; 2007 Sep; 117(9):2684-91. PubMed ID: 17710231
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term clinical outcome and phenotypic variability in hyperphosphatemic familial tumoral calcinosis and hyperphosphatemic hyperostosis syndrome caused by a novel GALNT3 mutation; case report and review of the literature.
    Rafaelsen S; Johansson S; Ræder H; Bjerknes R
    BMC Genet; 2014 Sep; 15():98. PubMed ID: 25249269
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Familial tumoral calcinosis: from characterization of a rare phenotype to the pathogenesis of ectopic calcification.
    Sprecher E
    J Invest Dermatol; 2010 Mar; 130(3):652-60. PubMed ID: 19865099
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Phex mutation in a murine model of X-linked hypophosphatemia alters phosphate responsiveness of bone cells.
    Ichikawa S; Austin AM; Gray AK; Econs MJ
    J Bone Miner Res; 2012 Feb; 27(2):453-60. PubMed ID: 22006791
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel recessive mutation of fibroblast growth factor-23 in tumoral calcinosis.
    Masi L; Gozzini A; Franchi A; Campanacci D; Amedei A; Falchetti A; Franceschelli F; Marcucci G; Tanini A; Capanna R; Brandi ML
    J Bone Joint Surg Am; 2009 May; 91(5):1190-8. PubMed ID: 19411468
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.